Exosla Therapeutics produces off‑the‑shelf extracellular vesicle (EV) immunotherapies derived from immortalized mesenchymal stem cell lines, delivering cell‑free, ready‑to‑administer products that modulate inflammation and promote tissue repair. Their GMP‑compatible, scalable manufacturing ensures consistent batch quality and extended shelf‑life for applications in neuroinflammatory injury, autoimmune disorders, and ocular diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Current immunotherapies for neuroinflammation, autoimmune disorders, and ophthalmic diseases often rely on live cell products that require complex manufacturing, have limited shelf‑life, and exhibit batch‑to‑batch variability, restricting their scalability and consistent clinical performance.
Solution
Exosla Therapeutics offers off‑the‑shelf extracellular vesicle (EV) immunotherapies derived from immortalized mesenchymal stem cell (MSC) lines. These EVs provide multimodal signaling that modulates immune responses and promotes tissue repair without the logistical challenges of live cell therapies. The platform uses standardized, scalable manufacturing processes and rigorous quality control to ensure consistent batch performance. By delivering a cell‑free, ready‑to‑administer product, Exosla enables rapid deployment in clinical settings for neuroinflammatory injury, autoimmune conditions, and ocular diseases. The approach leverages over a decade of MSC‑EV research to translate pre‑clinical efficacy into a reproducible therapeutic modality.
Target Audience
Primary customers are pharmaceutical and biotech companies developing immunotherapies, as well as academic and clinical research groups focused on neuroinflammation, autoimmune pathology, and ocular disease treatment.
Features
- EVs sourced from monoclonal, immortalized MSC lines ensuring unlimited drug supply and consistent product characteristics
- Scalable, GMP‑compatible manufacturing workflow with validated quality control to minimize batch variability
- Multimodal signaling payloads that simultaneously modulate inflammation, support neuroplasticity, and enhance tissue regeneration
- Cell‑free formulation that offers extended shelf‑life, simplified storage, and off‑the‑shelf availability
- Proprietary assays for functional immunomodulatory activity, enabling precise potency assessment
- Applicable across multiple indications, including neonatal hypoxic‑ischemic brain injury, autoimmune diseases, and ophthalmic disorders